We shown that, in contrast to classical opioid receptors, ACKR3 won't trigger classical G protein signaling and isn't modulated through the classical prescription or analgesic opioids, which include morphine, fentanyl, or buprenorphine, or by nonselective opioid antagonists including naloxone. Rather, we set up that LIH383, an ACKR3-selective subnanomolar competitor https://mikhailb404mkk6.wikiannouncement.com/user